PPARG and prostate carcinoma: PPARγ actions in prostate cancer cell lines [171]and primary cancer models [120] are well documented and include the induction of typeII programmed cell death also known as autophagy [112].These studies encouraged several groups to undertake clinical trials with PPARγ ligands and disease stabilization wasreported [115].Again in this disease setting, PPARγ-independent actions of TZDs were apparently identified, which werenonetheless potent anticancer signals [172, 173].